liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Improving the efficacy of cancer immunotherapy
St Georges University.
St Georges University.
Leiden University.
Argos Therapeut.
Vise andre og tillknytning
2009 (engelsk)Inngår i: EUROPEAN JOURNAL OF CANCER, ISSN 0959-8049, Vol. 45, nr 8, s. 1424-1431Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

A series of cancer vaccines have been evaluated in clinical trials with encouraging results, but the demonstration of clinical benefit in confirmatory studies has so far proven to be difficult. The development of cancer vaccines is hampered by a range of issues particular to this field of research. On 12th March 2008, the Biotherapy Development Association convened a workshop to discuss issues faced by scientists and clinicians involved in the development of cancer vaccines. This paper is a review of the field, based on discussions held at the BDA workshop, and describes biological barriers encountered in generating effective immune responses to tumours, methodological obstacles encountered in the improvement of immunological monitoring which aims to improve inter-laboratory and inter-trial comparisons, challenges in clinical trial design and problems posed by the lack of specific regulation for cancer vaccines and the impact on their development. Ultimately, a number of general solutions are posed: (1) better patient selection, (2) use of multi-modal treatments that affect several aspects of the immune system at once, (3) a requirement for the development of good biomarkers to stratify patients for selection prior to trial and as surrogates for clinical response and (4) harmonisation of SOPs for immunological monitoring of clinical trials.

sted, utgiver, år, opplag, sider
2009. Vol. 45, nr 8, s. 1424-1431
Emneord [en]
Immunotherapy, Cancer vaccine, Clinical response, Immunological monitoring, Combination therapy, Immunosupression, End-points, Surrogate end-points
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-19404DOI: 10.1016/j.ejca.2008.12.017OAI: oai:DiVA.org:liu-19404DiVA, id: diva2:224925
Tilgjengelig fra: 2009-06-23 Laget: 2009-06-22 Sist oppdatert: 2010-05-24

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekst
Av organisasjonen

Søk utenfor DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 76 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf